Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06187103 · ClinicalTrials.gov registry record · NA

Evaluation of Improved Onboard Patient Imaging

A NA study of Breast Cancer and Lung Cancer, sponsored by Varian, a Siemens Healthineers Company.

Active
Registry status
NA
Development phase
40
Enrollment target
1
Study location

NCT06187103: Active NA study of Breast Cancer and Lung Cancer, sponsored by Varian, a Siemens Healthineers Company.

NCT06187103 is a NA study of Breast Cancer and Lung Cancer that is active but no longer recruiting, run by Varian, a Siemens Healthineers Company. The registered enrollment target is 40 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06187103, a NA study of Breast Cancer and Lung Cancer, is active but no longer recruiting, sponsored by Varian, a Siemens Healthineers Company.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

The primary objective of radiation therapy is to deliver a therapeutic dose of radiation precisely to the target while minimizing exposure to healthy surrounding tissues. Image-guided radiation therapy (IGRT) involves acquiring cone beam computed tomography (CBCT) scans just before or during treatment sessions. By comparing the CBCT images with the reference images from the treatment planning process, clinicians can make necessary adjustments to ensure precise targeting and account for any changes that may have occurred since the initial planning. Conventional CBCT technology is, however, limited by several factors including long acquisition times that result in motion artifacts in the image, smaller fields of view that limit the volume of anatomy that can be imaged, poor image quality that limits soft tissue visibility, and artifacts created by dense metal implants. This study will evaluate a novel CBCT imaging solution ("HyperSight") that has the potential to address the challenges of conventional CBCT.

Primary Outcome

To evaluate the feasibility of HyperSight CBCT as a method for CBCT-based re-planning by measuring the fraction of patients whose HyperSight imaging meets criteria for potential CBCT-based treatment planning using HyperSight CBCT. The criteria include visibility of all key anatomical structures, image quality sufficient to contour anatomical structures, and clinically acceptable dose accuracy.

Interventions

  • DEVICE HyperSight Imaging

Study Locations (1)

Maryland

  • University of Maryland Medical Center - Baltimore

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2024-07-10
Est. Completion 2026-12
Phase NA

What the registry record for NCT06187103 still lists

NCT06187103 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower).

The record links to 5 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which HyperSight Imaging is the first listed.

NCT06187103 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT06187103 about?

NCT06187103 is a clinical study titled "Evaluation of Improved Onboard Patient Imaging". The primary objective of radiation therapy is to deliver a therapeutic dose of radiation precisely to the target while minimizing exposure to healthy surrounding tissues. Image-guided radiation therapy (IGRT) involves acquiring cone beam computed tomography (CBCT) scans just before or during treatme...

What is the current status of trial NCT06187103?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2024-07-10. Estimated completion is 2026-12.

What conditions does trial NCT06187103 study?

This clinical trial studies the following conditions: Breast Cancer, Lung Cancer, Head and Neck Cancer, Pelvic Cancer, Upper Gastrointestinal Cancer.

What interventions are being tested in trial NCT06187103?

The interventions under investigation include: HyperSight Imaging (DEVICE).

Who is sponsoring clinical trial NCT06187103?

This trial is sponsored by Varian, a Siemens Healthineers Company, which has 16 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06187103 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06187103's enrollment target sits among peer trials

40 876th of 1224 higher than 325 of 1,224 other Breast Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06187103, the US trial registry maintained by the National Library of Medicine. NCT06187103 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.